Vistin Pharma is strongly committed to maintaining an open dialogue with our shareholders, potential investors, analysts, investment banks and the financial markets.

Our goal is for the share price to reflect the underlying value of the company by providing all price-relevant information to the market.
Last updated 29.03 2022 11:00
Nok 16,80
Since open-0,30 (-1.70%)
Since previous close +0,44 (+2.60%)

8 reasons for investing in Vistin Pharma ASA.

Leading Producer
Amongst Top 5 producers of metformin HCl globally
High Quality Reputation
Leading reputation as producer of high quality APIs with strong track record of customer delivery
Attractive Market Dynamics
Established position in growing metformin market
Diverse Client Portfolio
Established client base comprising mix of Big Pharma and leading generics players
Sustained Revenue Growth
Strong growth profile with double digit revenue growth in the last 5 years
Advanced Manufacturing Facilities
State of the art and dedicated manufacturing facility with potential for further expansion
Strong Leadership
Experienced management team with a strong track record
A Front-runner
Leading the ESG culture in the industry

Quarterly Results

Annual Reports

Other downloads

Investor calendar

17.2.23
Q4 and Preliminary figures 2022
27.4.23
Annual Report 2022
27.4.23
Q1 2023 report
22.5.23
Ordinary General Meeting
23.8.23
Q2 and Half-year report 2023
25.10.23
Q3 2023 report

Main shareholders

NAME

Per 30 november 2023

SHAREHOLDING

% SHARE

TOM RAGNAR PRESTEGÅRD STAAVI
526 324
DELTA AS
410 000
PACTUM AS*
3 519 733
AUGUST RINGVOLD AGENTUR AS
750 315
SANDEN EQUITY AS
468 947
STORKLEIVEN AS
751 000
HOLMEN SPESIALFOND
3 801 055
DNB BANK ASA
500 000
IVAR LØGES STIFTELSE
550 000
MP PENSJON PK
1 719 848
HENRIK MIDTTUN HAAVIE
601 416
INTERTRADE SHIPPING AS*
12 575 000
CORTEX AS
508 989
WEM INVEST AS
500 000
LUCELLUM AS
720 000
FERNCLIFF LISTED DAI AS*
1 234 280
ØYSTEIN STRAY SPETALEN*
323 650
Imported item 24
NIELS CATO BECKETT AALL
301 658
Imported item 23
Imported item 22
GINKO AS
400 000
NICOLAI ANDREAS EGER
284 040
Total 20 largest shareholders
30 332 392
68,40%
Other shareholders
14 012 200
31,60%
Total number of shares
44 344 592
100%
* Board members of Vistin Pharma, or companies controlled by Board members
Vistin Pharma - Oslo Stock Exchange

Contact

Alexander Karlsen
CFO
Vistin Pharma ASA
+47 970 53 621alexander.karlsen@vistin.com
Alexander Karlsen